2024-09-17
1. Summary of the week
Between September 7 and 13, a total of 14 licensing and collaboration deals were signed globally. In China’s biotech sector, CenterGene Pharmaceuticals entered an out-licensing agreement with Organon for SJ02, securing an upfront payment of $12 million. Additionally, Harbour BioMed and Umoja BioPharma formed a partnership to develop pre-clinical CAR designs for novel drug candidates.
Globally, 12 licensing and cooperation agreements were concluded during the same week. The largest deal of the week was between Orano Med, RadioMedix, and Sanofi for the Phase II oncology asset 212Pb-dotamtate, valued at $346 million, including an upfront payment of $108 million.
9月7日到13日，全球医药市场共完成了14项授权和合作协议，中国医药市场占了2项，均为出海交易。晟济药业将SJ02在中国大陆的独家商业化权益转让给欧加农，首付款1200万美元。诺纳生物/和铂医药与Umoja Biopharma达成合作，共同推进体内CAR-T细胞疗法开发。
在全球范围内，共签署了12项协议。其中最大的一项交易是赛诺菲与Orano Med和RadioMedix就二期肿瘤资产212Pb-dotamtate达成的授权交易，首付款1.08亿美元，总价值高达3.46亿美元。
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
5. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit http://www.yafocapital.com
ACCESS CHINA
Event Name:
2024-09 药通中国秋季路演，线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM，线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco
BioToChina.org 